Branched Chain Amino Acids Are Associated with Physical Performance in Patients with End-Stage Liver Disease

Decreased circulating branched chain amino acids (BCAA) represent a prominent change in amino acid profiles in patients with end-stage liver disease (ESLD). These alterations are considered to contribute to sarcopenia and hepatic encephalopathy and may relate to poor prognosis. Here, we cross-sectionally analyzed the association between plasma BCAA levels and the severity of ESLD and muscle function in participants of the liver transplant subgroup of TransplantLines, enrolled between January 2017 and January 2020. Plasma BCAA levels were measured by nuclear magnetic resonance spectroscopy. Physical performance was analyzed with a hand grip strength test, 4 m walking test, sit-to-stand test, timed up and go test, standing balance test and clinical frailty scale. We included 92 patients (65% men). The Child Pugh Turcotte classification was significantly higher in the lowest sex-stratified BCAA tertile compared to the highest tertile (p = 0.015). The times for the sit-to-stand (r = −0.352, p < 0.05) and timed up and go tests (r = −0.472, p < 0.01) were inversely correlated with total BCAA levels. In conclusion, lower circulating BCAA are associated with the severity of liver disease and impaired muscle function. This suggests that BCAA may represent a useful prognostic marker in the staging of liver disease severity.

[1]  H. El‐Nezami,et al.  The Emerging Role of Branched-Chain Amino Acids in Liver Diseases , 2022, Biomedicines.

[2]  G. Nava,et al.  Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer , 2022, Expert review of molecular diagnostics.

[3]  M. Connelly,et al.  Branched Chain Amino Acids are associated with Metabolic Complications in Liver Transplant Recipients. , 2022, Clinical biochemistry.

[4]  J. Churilla,et al.  Branched chain amino acid-inflammation relationship in youth with obesity: A randomized controlled intervention study. , 2021, The Journal of clinical endocrinology and metabolism.

[5]  Olasunkanmi A J Adegoke,et al.  Branched-chain Amino Acids: Catabolism in Skeletal Muscle and Implications for Muscle and Whole-body Metabolism , 2021, Frontiers in Physiology.

[6]  A. Bell,et al.  The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone , 2021, Seminars in Liver Disease.

[7]  Y. Chawla,et al.  Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver. , 2020, Journal of clinical and experimental hepatology.

[8]  S. Pungpapong,et al.  Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. , 2020, Annals of hepatology.

[9]  M. Connelly,et al.  Concentration of Branched-Chain Amino Acids Is a Strong Risk Marker for Incident Hypertension. , 2019, Hypertension.

[10]  Michael Neinast,et al.  Branched Chain Amino Acids. , 2019, Annual review of physiology.

[11]  Lyanne M. Kieneker,et al.  Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study , 2018, Journal of clinical medicine.

[12]  G. Drost,et al.  Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients , 2018, BMJ Open.

[13]  S. Baik,et al.  Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score , 2018, Journal of cachexia, sarcopenia and muscle.

[14]  D. Mager,et al.  Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review. , 2018, Clinical nutrition ESPEN.

[15]  K. Tajiri,et al.  Branched-chain amino acids in liver diseases. , 2018, Translational gastroenterology and hepatology.

[16]  M. Holeček.  Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements , 2018, Nutrition & Metabolism.

[17]  M. Connelly,et al.  A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness. , 2018, Clinical biochemistry.

[18]  J. Ijzermans,et al.  A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. , 2017, Journal of hepatology.

[19]  M. Scholz,et al.  Plasma Amino Acid Concentrations Predict Mortality in Patients with End-Stage Liver Disease , 2016, PloS one.

[20]  M. Sawyer,et al.  Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis , 2015, Clinical and Translational Gastroenterology.

[21]  M. Connelly,et al.  NMR measurement of LDL particle number using the Vantera Clinical Analyzer. , 2014, Clinical biochemistry.

[22]  J. Ryu,et al.  Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites , 2014, Journal of Korean medical science.

[23]  Philip Wong,et al.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.

[24]  M. Holeček.  Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications. , 2013, Nutrition.

[25]  T. Ganten,et al.  Liver allocation: urgency of need or prospect of success? Ethical considerations , 2013, Clinical transplantation.

[26]  H. Imanishi,et al.  Association of amino acid imbalance with the severity of liver fibrosis and esophageal varices. , 2013, Annals of hepatology.

[27]  M. Manns,et al.  The introduction of MELD‐based organ allocation impacts 3‐month survival after liver transplantation by influencing pretransplant patient characteristics , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[28]  J. Neuberger.  The introduction of MELD‐based organ allocation impacts 3‐month survival after liver transplantation by influencing pretransplant patient characteristics , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[29]  F. Chang,et al.  Limitation of the model for end‐stage liver disease for outcome prediction in patients with cirrhosis‐related complications , 2006, Clinical transplantation.

[30]  T. Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001 .

[31]  A. Kao.  Revising the declaration of helsinki. , 2001, The virtual mentor : VM.

[32]  M. Suzuki,et al.  Influence of alcohol on branched-chain amino acid/tyrosine molar ratio in patients with cirrhosis. , 1998, Alcoholism, clinical and experimental research.

[33]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[34]  Paul A. Keifer,et al.  WET Solvent Suppression and Its Applications to LC NMR and High-Resolution NMR Spectroscopy , 1995 .

[35]  N. Mcintyre,et al.  The BCAA/AAA ratio of plasma amino acids in three different groups of cirrhotics. , 1992, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[36]  S. Sherlock,et al.  Plasma amino-acid patterns in liver disease. , 1982, Gut.

[37]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[38]  M. Holeček.  Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. , 2015, Nutrition.

[39]  Y. Muto,et al.  Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication , 2008, Gastroenterologia Japonica.

[40]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[41]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.